RedHill Biopharma posts corporate presentation on Talicia commercialization, late-stage GI and oncology pipeline

  • RedHill outlined a U.S.-focused specialty pharma strategy centered on GI, infectious disease, oncology commercialization, led by Talicia for H. pylori.
  • FY 2025 net revenue USD 7.8 million; gross margin 74.6%; cash balance USD 4.1 million; market cap about USD 5.2 million.
  • Equity financing capacity cited at USD 31.7 million under its market purchase agreement, SEPA.
  • Talicia positioned as leading branded H. pylori prescription among U.S. gastroenterologists; U.S. patent protection cited through 2042; QIDP exclusivity through 2027.
  • Pipeline focus includes opaganib in Phase 2 prostate cancer combination study with Bayer’s darolutamide; RHB-204 positioned as Phase 3-stage for pulmonary NTM disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.